CN114144169A - 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法 - Google Patents

醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法 Download PDF

Info

Publication number
CN114144169A
CN114144169A CN202080052698.5A CN202080052698A CN114144169A CN 114144169 A CN114144169 A CN 114144169A CN 202080052698 A CN202080052698 A CN 202080052698A CN 114144169 A CN114144169 A CN 114144169A
Authority
CN
China
Prior art keywords
leuprolide
release composition
subject
extended release
flowable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080052698.5A
Other languages
English (en)
Chinese (zh)
Inventor
J.米德尔顿
A.南吉亚
J.A.麦克莱恩
T.L.莫顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tolmar International Ltd
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of CN114144169A publication Critical patent/CN114144169A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202080052698.5A 2019-05-27 2020-05-26 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法 Pending CN114144169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
US62/853,153 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (1)

Publication Number Publication Date
CN114144169A true CN114144169A (zh) 2022-03-04

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052698.5A Pending CN114144169A (zh) 2019-05-27 2020-05-26 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法

Country Status (17)

Country Link
US (2) US12453754B2 (https=)
EP (1) EP3975990A1 (https=)
JP (1) JP7664855B2 (https=)
KR (1) KR20220041782A (https=)
CN (1) CN114144169A (https=)
AR (1) AR119021A1 (https=)
AU (1) AU2020284587B2 (https=)
BR (1) BR112021023904A2 (https=)
CA (1) CA3141456A1 (https=)
EA (1) EA202193257A1 (https=)
IL (1) IL288503A (https=)
MX (1) MX2021014540A (https=)
PH (1) PH12021552976A1 (https=)
SG (1) SG11202112888RA (https=)
TW (1) TWI757753B (https=)
UY (1) UY38717A (https=)
WO (1) WO2020240417A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400363A (zh) * 2006-01-18 2009-04-01 Qps有限公司 具有增强的稳定性的药物组合物
CN104334189A (zh) * 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DK3660073T3 (da) * 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
CN114144169A (zh) 2019-05-27 2022-03-04 托尔玛国际有限公司 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
DK4135830T3 (da) 2020-12-23 2024-10-28 Tolmar International Ltd Systemer og fremgangsmåder til blanding af sprøjteventilanordninger
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400363A (zh) * 2006-01-18 2009-04-01 Qps有限公司 具有增强的稳定性的药物组合物
CN104334189A (zh) * 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARISH B.: "Sustained Suppression of Pituitary-Gonadal Axis with an Injectable, In Situ Forming Implant of Leuprolide Acetate", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 89, no. 6, 1 June 2000 (2000-06-01), pages 732 - 741, XP055143312, DOI: 10.1002/(SICI)1520-6017(200006)89:6<732::AID-JPS4>3.0.CO;2-D *
HARISH B: "Sustained Activity and Release of Leuprolide Acetate from an In Situ Forming Polymeric Implant", AAPS PHARMSCITECH, vol. 1, no. 1, 1 January 2000 (2000-01-01), pages 1 - 8, XP055143271, DOI: 10.1208/pt010101 *

Also Published As

Publication number Publication date
WO2020240417A1 (en) 2020-12-03
KR20220041782A (ko) 2022-04-01
MX2021014540A (es) 2022-04-12
AR119021A1 (es) 2021-11-17
TW202110472A (zh) 2021-03-16
IL288503A (en) 2022-01-01
TWI757753B (zh) 2022-03-11
SG11202112888RA (en) 2021-12-30
AU2020284587A1 (en) 2022-01-06
UY38717A (es) 2020-11-30
US12453754B2 (en) 2025-10-28
EA202193257A1 (ru) 2022-03-10
PH12021552976A1 (en) 2022-07-04
AU2020284587B2 (en) 2025-09-18
BR112021023904A2 (pt) 2022-02-01
US20220265760A1 (en) 2022-08-25
US20260027176A1 (en) 2026-01-29
JP2022535694A (ja) 2022-08-10
JP7664855B2 (ja) 2025-04-18
EP3975990A1 (en) 2022-04-06
CA3141456A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
US20260027176A1 (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
Sheleg et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme
Rusthoven et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
US11229599B2 (en) Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
Ledwitch et al. Taxol: efficacy against oral squamous cell carcinoma
Carnaghi et al. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer
Begg et al. Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors
EP3746047B1 (en) Injectable composition
CN100464736C (zh) 同载抗代谢药物及其增效剂的抗癌缓释注射剂
EP2957287B1 (en) Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier
EA046538B1 (ru) Применение лейпролида для подавления функции яичников у субъекта с гормон-рецептор-положительным раком молочной железы
Eichler et al. Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study
US11110303B2 (en) Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
CN120361228B (zh) 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物
JP4020256B2 (ja) 前立腺癌の局所治療剤
Wang et al. Synergistic Thermochemotherapy via Injectable Polyurethane Hydrogel Co‐Delivering Cisplatin and 17AAG for Peritoneal Metastasis of Colorectal Cancer
TW202532086A (zh) 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法
CN100431607C (zh) 一种抗实体肿瘤的药物组合物
KR102356393B1 (ko) 두경부암의 치료 또는 예방에 사용하기 위한 pi3 키나제 억제제와 파클리탁셀의 조합물
CN101297970A (zh) 同载抗代谢药物及其增效剂的抗癌缓释注射剂
WO2019110688A1 (en) A composition comprising degarelix for use in the treatment of breast cancer
CN101283974A (zh) 一种抗癌缓释凝胶注射剂及其制备方法
EP1119361A2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
CN101336898A (zh) 同载铂类药物及其增效剂的抗癌缓释剂
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination